In patients with T2D, large CV outcome trials have shown that sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have beneficial cardioprotective effects [2–7], regardless of the presence of established atherosclerotic CV disease or history of heart failure (HF) [6, 8], with reduction in major adverse CV events and CV deaths, as well as reduced risk of hospitalization for HF, and reduced progression of renal disease and all-cause mortality [9–14]. This evidence concerns the gene SLC5A2 and heart failure.